Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial

Yao-Chun Hsu, Chi-Yi Chen, Cheng-Hao Tseng, Chieh-Chang Chen, Teng-Yu Lee, Ming-Jong Bair, Jyh-Jou Chen, Yen-Tsung Huang, I-Wei Chang, Chi-Yang Chang, Chun-Ying Wu, Ming-Shiang Wu, Lein-Ray Mo, Jaw-Town Lin

Clin Mol Hepatol. 2025;31(1):213-226. Published online October 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0640

View: 1554 Download: 155

Correspondence

Correspondence to editorial on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”

Xiaoqian Xu, Hong You, Jidong Jia, Yuanyuan Kong

Clin Mol Hepatol. 2024;30(4):994-996. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0552

View: 1361 Download: 34 Web of Science: 1 Crossref: 1

Editorial

Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients”

Hae Lim Lee, Jeong Won Jang

Clin Mol Hepatol. 2024;30(4):692-694. Published online May 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0346

View: 1502 Download: 55

Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”

Beom Kyung Kim

Clin Mol Hepatol. 2024;30(4):656-658. Published online July 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0499

View: 1317 Download: 36 Crossref: 2

Correspondence

Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring

Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu

Clin Mol Hepatol. 2024;30(2):293-296. Published online February 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0101

View: 2232 Download: 68

Review

Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus

Sun Woong Kim, Jun Sik Yoon, Minjong Lee, Yuri Cho

Clin Mol Hepatol. 2022;28(1):17-30. Published online July 20, 2021

DOI: https://doi.org/10.3350/cmh.2021.0093

View: 12341 Download: 664 Web of Science: 43 Crossref: 44

Management of viral hepatitis in liver transplant recipients

Soung Won Jeong, YoungRok Choi, Jin-Wook Kim

Clin Mol Hepatol. 2014;20(4):338-344. Published online December 24, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.4.338

View: 9462 Download: 81 Web of Science: 3 Crossref: 3

2

HBV Mutations During Antiviral Therapy in Patients with Chronic Hepatits B

Seong Gyu Hwang

Clin Mol Hepatol. 2005;11(4):311-319. Published online January 1, 1970

View: 2674 Download: 14

Treatment of Chronic Hepatitis B ; Monitoring Patients with Chronic HBV Infection During Antiviral Therapy

Yun Soo Kim

Clin Mol Hepatol. 2005;11(1):9-12. Published online January 1, 2000

View: 2697 Download: 17

Original Article

Switching to Besifovir in Patients with Chronic Hepatitis B Receiving Tenofovir Disoproxil Fumarate: A Randomized Trial

Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, Won Kim, Young Kul Jung, Jae Young Jang, Sae Hwan Lee, Yun Soo Kim, Chang Wook Kim, Hyoung Su Kim, Jae-Jun Shim, Eun-Young Cho, In Hee Kim, Byung Seok Lee, Jeong-Hoon Lee, Byung Seok Kim, Jeong Won Jang, Hyun Woong Lee, Jung Hyun Kwon, Moon Young Kim, Do Seon Song, Jung Gil Park, Yoon Seok Lee, Eileen L. Yoon, Han Ah Lee, Seong Hee Kang, Jin Mo Yang

Received September 19, 2024 Accepted January 16, 2025

DOI: https://doi.org/10.3350/cmh.2024.0819 [Accepted]

View: 1411 Download: 70

Correspondence

Revisiting unmet needs in clinical research on direct-acting antiviral therapy for HCC patients

Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu

Received April 2, 2025 Accepted April 2, 2025

DOI: https://doi.org/10.3350/cmh.2025.0362 [Accepted]

View: 221 Download: 9

1 |

Viewed By 8717	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7547	MAFLD: How is it different from NAFLD?
Viewed By 5446	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5047	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4576	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 322	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 292	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 203	MAFLD: How is it different from NAFLD?
Cited By 101	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 92	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search